Surgical Robotics Under Pressure as Approvals Advance

Intuitive Surgical ($ISRG) remains in focus after recent trading weakness, with shares closing at $406.78 following a 27.6% year-to-date decline. The surgical robotics leader has posted a 7.1% decline over the past month and 2.3% drop over the past week, with one-year returns down 21.0%. Despite the selloff, three-year and five-year returns stand at 25.1% and 33.7% respectively, and recent analysis suggests the stock could be 23.6% undervalued at current levels. The company continues to dominate minimally invasive surgical technology, though questions persist around whether valuation expectations have reset sufficiently after the sustained drawdown.

DexCom ($DXCM) received an upgraded price target from Piper Sandler, with analyst Matt O'Brien raising the firm's target to $88 from $75 while maintaining an Overweight rating on the continuous glucose monitoring device manufacturer. The diagnostics and wearables segment continues to attract positive analyst attention as diabetes management technology advances.

AbbVie ($ABBV) announced that its Allergan Aesthetics division received FDA approval for Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over age 21, expanding the franchise beyond its established facial applications. The approval represents a label expansion for the hyaluronic acid-based injectable aesthetic platform.

Merck ($MRK) disclosed that the FDA approved KEYTRUDA and the easier-to-administer KEYTRUDA QLEX, each in combination with WELIREG, for kidney cancer treatment. The approval deepens $MRK's renal cell carcinoma franchise by adding the oral HIF-2α inhibitor WELIREG to its blockbuster PD-1 inhibitor platform. Merck made up 2.91% of the O'Shares U.S. Quality Dividend ETF as of June 17, 2026.

Eli Lilly ($LLY) entered into a research and collaboration agreement with BioArctic AB combining an undisclosed Lilly drug candidate in neurodegeneration with BioArctic's proprietary BrainTransporter technology. BioArctic will receive $30 million in upfront payment as part of the deal, which aims to enhance central nervous system drug delivery for potential treatments in neurodegenerative disease.

Johnson & Johnson ($JNJ) announced an investment of more than $1 billion in Jacksonville, Florida, to expand its vision care manufacturing operations. The capital deployment strengthens $JNJ's U.S. manufacturing footprint in the contact lens and ophthalmic device segment. Johnson & Johnson made up 5.33% of the O'Shares U.S. Quality Dividend ETF as of June 17, 2026, and remains a core holding in Kevin O'Leary's top stock picks for 2026.

The Healthcare Select Sector SPDR ETF sits at $149, down approximately 3% year-to-date, while recent analysis suggests two key factors will determine whether the fund catches the broader S&P 500 in 2026. Big Pharma dividend names including $PFE and $JNJ continue to attract attention from income-focused investors as passive dividend strategies gain traction. Investors are monitoring whether regulatory tailwinds from recent FDA approvals can offset valuation pressure in high-multiple medical technology names, particularly in the surgical robotics and diagnostics segments where growth expectations remain elevated despite recent selloffs.